Pacira BioSciences (PCRX) Stock Analysis

What Pacira BioSciences does

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Key metrics

ETFs linked to PCRX

Broad-market and Healthcare sector ETFs an investor holding Pacira BioSciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PCRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pacira BioSciences?

Pacira BioSciences trades under the ticker PCRX on NASDAQ.

Which exchange is PCRX listed on?

PCRX is listed on NASDAQ.

What sector does Pacira BioSciences operate in?

Pacira BioSciences is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze PCRX in a portfolio?

PortView shows PCRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.